Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
暂无分享,去创建一个
L. Chirieac | R. Plummer | M. Ranson | G. Shapiro | J. Schellens | R. Carvajal | D. Boss | C. Morris | H. Swaisland | M. Middleton | H. Calvert | S. Danson | R. Midgley | D. Amakye | G. Schwartz | Geoffrey I. Shapiro | Malcolm R Ranson | Richard D. Carvajal | M. R. Middleton | Ruth Plummer | J. H. Schellens | Gary K. Schwartz | Rachel Midgley | Sarah Danson | Hilary Calvert | Clive Morris | Lucian R. Chirieac
[1] M. Salto‐Tellez,et al. Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer , 2009, Clinical Cancer Research.
[2] G. Shapiro,et al. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. , 2008, Clinical lung cancer.
[3] D. Camidge,et al. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers , 2007, Cancer Chemotherapy and Pharmacology.
[4] D. Camidge,et al. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers , 2007, Cancer Chemotherapy and Pharmacology.
[5] G. Shapiro,et al. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. , 2006, Cancer research.
[6] G. Shapiro,et al. Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Kate F. Byth,et al. The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor , 2006, Molecular Cancer Therapeutics.
[8] G. Shapiro,et al. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. , 2006, Cancer research.
[9] M. Shah,et al. Targeting the cell cycle: a new approach to cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Sloan,et al. Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points , 2005, Clinical Cancer Research.
[11] M. Loda,et al. A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.
[12] Peter Lassota,et al. Bioluminescent imaging of Cdk2 inhibition in vivo , 2004, Nature Medicine.
[13] S. Wedge,et al. Novel approaches in oncology at AstraZeneca , 2003 .
[14] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[15] Harbour Jw,et al. Inactivation of Retinoblastoma Protein in Uveal Melanoma by Phosphorylation of Sites in the COOH-Terminal Region , 2000 .
[16] E. Vokes,et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Harbour,et al. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. , 2000, Cancer research.
[18] J. Harbour,et al. Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1 , 1999, Cell.
[19] Robert A. Weinberg,et al. Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.
[20] Sibylle Mittnacht,et al. Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases* , 1997, The Journal of Biological Chemistry.
[21] M. Loda,et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.
[22] S. Reed. Control of the G1/S transition. , 1997, Cancer surveys.
[23] C. Sherr. Cancer Cell Cycles , 1996, Science.
[24] M. Kitagawa,et al. The consensus motif for phosphorylation by cyclin D1‐Cdk4 is different from that for phosphorylation by cyclin A/E‐Cdk2. , 1996, The EMBO journal.
[25] J. Pines,et al. The cell cycle kinases. , 1994, Seminars in cancer biology.